Filing Flows › Biogen (BIIB) › Capital expenditures
Biogen (BIIB) capital expenditures by quarter
Biogen's capital expenditures were $40.4M in Q3 2026 (third quarter 2026), -1% from Q2 2026. Over the last 7 quarters it ranged from $26.6M (Q2 2025) to $51.2M (Q1 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $40.4M | -1% | -13% |
| Q2 2026 | $40.9M | -20% | +54% |
| Q1 2026 | $51.2M | +17% | +38% |
| Q4 2025 | $43.9M | -5% | — |
| Q3 2025 | $46.2M | +74% | — |
| Q2 2025 | $26.6M | -28% | — |
| Q1 2025 | $37.1M | — | — |
Q3 2026 at a glance
Biogen, Q3 2026: revenue $2.8B (+11% year over year), operating margin -0.3%, net loss $20.6M, operating cash flow $641M. The chart follows the revenue to costs, profit and cash.
Questions
What is Biogen's capital expenditures?
Biogen's capital expenditures were $40.4M in Q3 2026 (third quarter 2026), -1% from Q2 2026.
How has Biogen's capital expenditures changed?
Over the last 7 quarters it ranged from $26.6M (Q2 2025) to $51.2M (Q1 2026).